Molecular analysis of PML‐RARa fusion mRNA detected by reverse transcription‐polymerase chain reaction assay in long‐term disease‐free acute promyelocytic leukaemia patients
- 1 August 1995
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 90 (4) , 966-968
- https://doi.org/10.1111/j.1365-2141.1995.tb05228.x
Abstract
Summary. By use of RT‐PCR of PML/RARa, we evaluated bone marrow aspirates in 10 patients with APL in long‐term disease‐free status after induction chemotherapy and consolidation (median 54 months; range 33‐101 months from complete remission). All patients were in clinical and cytogenetic remission at the time of molecular evaluation (range 32‐96 months from CR). All patients but one were found to be RT‐PCR negative at the molecular level for the expression of PML‐RARa transcript, confirming that the majority of the patients with long‐term survival of APL are characterized by the eradication of the neoplastic clone.Keywords
This publication has 6 references indexed in Scilit:
- Four-chromosomes complex translocations in acute promyelocytic leukemia: Description of two casesEuropean Journal of Haematology, 2009
- Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long- term remissionBlood, 1993
- Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapseBlood, 1993
- Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaThe Lancet, 1992
- Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia.Proceedings of the National Academy of Sciences, 1992
- The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reactionBlood, 1992